Document is current
Any future updates will be listed below
-
Authors
Mulholland, Eoghan J. https://orcid.org/0000-0002-1200-9825
Belnoue-Davis, Hayley L. https://orcid.org/0000-0003-2914-4932
Valbuena, Gabriel N.
Gunduz, Nuray
Ligeza, Amelia
Lin, Muyang
Biswas, Sujata
Gil Vasquez, Ester
Omwenga, Sulochana
Nasreddin, Nadia
Hodder, Michael C.
Wang, Lai Mun
Ng, Aik Seng https://orcid.org/0000-0003-1925-4759
Jennings, Elizabeth
Midwood, Kim S. https://orcid.org/0000-0002-8813-2977
Dedi, Neesha https://orcid.org/0009-0000-7516-5449
Irshad, Shazia https://orcid.org/0000-0003-4536-373X
Ridgway, Rachel A. https://orcid.org/0000-0003-0198-8244
Phesse, Toby J. https://orcid.org/0000-0001-9568-4916
East, James https://orcid.org/0000-0001-8035-3700
Tomlinson, Ian PM https://orcid.org/0000-0003-3037-1470
Davies, Gareth CG https://orcid.org/0000-0001-5180-3143
Sansom, Owen J. https://orcid.org/0000-0001-9540-3010
Leedham, Simon J. https://orcid.org/0000-0003-1476-6982
-
Funding
Funding for this research was provided by:
University of Oxford (Lee Placito Fellowship)
Cancer Research UK (DRCNPG-Jun22\100002, A26825 and A28223)
Wellcome Trust (206314/Z/17/Z, 090532/Z/09/Z)
- License Information
-
More Information
Article History
Received: 8 April 2024
Accepted: 19 May 2025
First Online: 4 June 2025
Competing interests
: The named authors declare the following competing interests; S.J.L. has received grant income from UCB Pharma; G.D. was a UCB employee at the time the research was conducted; N.D. is an employee of UCB Pharma, UK and owns shares in UCB Pharma and Vertex Pharmaceuticals. All other authors declare no competing interests.
